Downregulation of YTHDF2 plays an important role in expansion of hematopoietic stem and progenitor cells (HSPC) and LSCs/LICs function (59–61), by leading to significant promotion of cell proliferation, colony formation, and reduction of apoptosis (32), which suggests it as a viable new target for AML therapy (35). The gene discussed is YTHDF2; the disease is acute myeloid leukemia.